Anticholinesterase drugs

Reading File
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Loading Image
Searching Images

anticholinesterase drugs mechanism classification neostigmine physostigmine organophosphate

This composite educational graphic details the neurobiological effects of physostigmine during emotion-recognition tasks in Bipolar Disorder (BD) and Healthy Controls (HC). The image is organized into three comparative panels (A, B, C), each containing a functional MRI (fMRI) brain scan and corresponding behavioral dot plots for accuracy and reaction time. Panel A shows sagittal brain activation where physostigmine increases activity in the right superior frontal gyrus (Brodmann Area 46) in BD patients compared to placebo. Panel B illustrates decreased activation in the left anterior cingulate cortex (BA32) in healthy controls following physostigmine administration relative to placebo. Panel C displays a direct contrast between the two groups under physostigmine influence, highlighting increased activation in the bilateral posterior/dorsal cingulate cortex (BA31) in BD patients relative to controls. The behavioral data plots indicate that while neurofunctional activation patterns shifted significantly (p<0.05), behavioral performance regarding recognition accuracy and reaction times remained largely unchanged across groups. This material illustrates the differential cholinergic impact on frontocingulate circuits involved in emotional processing and top-down regulation in mood disorders.

This composite educational graphic details the neurobiological effects of physostigmine during emotion-recognition tasks in Bipolar Disorder (BD) and Healthy Controls (HC). The image is organized into three comparative panels (A, B, C), each containing a functional MRI (fMRI) brain scan and corresponding behavioral dot plots for accuracy and reaction time. Panel A shows sagittal brain activation where physostigmine increases activity in the right superior frontal gyrus (Brodmann Area 46) in BD patients compared to placebo. Panel B illustrates decreased activation in the left anterior cingulate cortex (BA32) in healthy controls following physostigmine administration relative to placebo. Panel C displays a direct contrast between the two groups under physostigmine influence, highlighting increased activation in the bilateral posterior/dorsal cingulate cortex (BA31) in BD patients relative to controls. The behavioral data plots indicate that while neurofunctional activation patterns shifted significantly (p<0.05), behavioral performance regarding recognition accuracy and reaction times remained largely unchanged across groups. This material illustrates the differential cholinergic impact on frontocingulate circuits involved in emotional processing and top-down regulation in mood disorders.

A comparison of two anteroposterior (AP) erect abdominal X-rays demonstrating the radiological management of acute colonic pseudo-obstruction (Ogilvie's syndrome). The 'Before Neostigmine' image shows marked gaseous distention of the large and small bowel loops throughout the abdominal cavity, with prominent multiple air-fluid levels indicative of functional bowel obstruction. The 'After Neostigmine' image shows a significant reduction in bowel loop caliber and a decrease in the number and height of air-fluid levels, indicating successful pharmacological decompression. In the second image, a radiopaque nasogastric (NG) tube is visible, coursing from the upper midline into the left upper quadrant, terminating in the stomach for decompression. Additional monitoring leads are visible on the periphery. This comparison illustrates the clinical effectiveness of neostigmine, an acetylcholinesterase inhibitor, in restoring bowel motility and reducing intraluminal pressure in cases of pseudo-obstruction.

A comparison of two anteroposterior (AP) erect abdominal X-rays demonstrating the radiological management of acute colonic pseudo-obstruction (Ogilvie's syndrome). The 'Before Neostigmine' image shows marked gaseous distention of the large and small bowel loops throughout the abdominal cavity, with prominent multiple air-fluid levels indicative of functional bowel obstruction. The 'After Neostigmine' image shows a significant reduction in bowel loop caliber and a decrease in the number and height of air-fluid levels, indicating successful pharmacological decompression. In the second image, a radiopaque nasogastric (NG) tube is visible, coursing from the upper midline into the left upper quadrant, terminating in the stomach for decompression. Additional monitoring leads are visible on the periphery. This comparison illustrates the clinical effectiveness of neostigmine, an acetylcholinesterase inhibitor, in restoring bowel motility and reducing intraluminal pressure in cases of pseudo-obstruction.

This pathophysiology diagram illustrates the mechanism of pH-induced physiological drug resistance (PIPDR) and its circumvention via nanoparticle (NP) delivery. The diagram is divided into two clinical scenarios: normal tissue and tumor tissue. In normal tissue (extracellular pH 7.4), weakly basic drugs exist in uncharged forms and freely permeate the cell membrane to enter normal cells (intracellular pH 7.0–7.4). In the tumor microenvironment (extracellular pH 6.5–7.0), the acidic conditions cause the drug molecules to become protonated ([HD]+). These protonated forms are depicted as clustered aggregates with reduced membrane permeability, leading to decreased intracellular drug concentration in tumor cells. The lower section demonstrates the educational concept of NP-mediated delivery: drug-loaded nanoparticles enter tumor cells through endocytosis, bypassing pH-dependent membrane permeability barriers. Once inside the intracellular environment (pH 7.0–7.4), the drugs are released in their active, uncharged forms, effectively restoring therapeutic efficacy. The diagram uses color-coded arrows and chemical equilibrium equations to highlight how local pH gradients influence pharmacokinetics and how nanomedicine can overcome extracellular acidity-induced resistance.

This pathophysiology diagram illustrates the mechanism of pH-induced physiological drug resistance (PIPDR) and its circumvention via nanoparticle (NP) delivery. The diagram is divided into two clinical scenarios: normal tissue and tumor tissue. In normal tissue (extracellular pH 7.4), weakly basic drugs exist in uncharged forms and freely permeate the cell membrane to enter normal cells (intracellular pH 7.0–7.4). In the tumor microenvironment (extracellular pH 6.5–7.0), the acidic conditions cause the drug molecules to become protonated ([HD]+). These protonated forms are depicted as clustered aggregates with reduced membrane permeability, leading to decreased intracellular drug concentration in tumor cells. The lower section demonstrates the educational concept of NP-mediated delivery: drug-loaded nanoparticles enter tumor cells through endocytosis, bypassing pH-dependent membrane permeability barriers. Once inside the intracellular environment (pH 7.0–7.4), the drugs are released in their active, uncharged forms, effectively restoring therapeutic efficacy. The diagram uses color-coded arrows and chemical equilibrium equations to highlight how local pH gradients influence pharmacokinetics and how nanomedicine can overcome extracellular acidity-induced resistance.

A pathophysiology diagram illustrating three primary mechanisms of azole drug resistance in Aspergillus fumigatus. Mechanism A (Reduced azole affinity) shows a brown cyp51A gene with lightning bolt symbols representing single amino acid substitutions (G54, P216, F219, M220, G448), resulting in mutated CYP51A enzymes that cannot bind azole drugs. Mechanism B (Overexpression of CYP51A) depicts a green cyp51A gene with a TR34/L98H mutation in the promoter region, leading to increased mRNA transcription and a high concentration of target enzymes. Mechanism C (Overexpression of efflux transporter) illustrates multiple blue cylindrical Cdr1B transporters embedded in the cell membrane, using blue arrows to show the active expulsion of azole drugs (represented by brown triangles) from the intracellular space. This medical illustration provides a clear visual summary of genetic mutations and protein overexpression strategies used by fungal pathogens to evade antifungal treatments targeting the ergosterol synthesis pathway.

A pathophysiology diagram illustrating three primary mechanisms of azole drug resistance in Aspergillus fumigatus. Mechanism A (Reduced azole affinity) shows a brown cyp51A gene with lightning bolt symbols representing single amino acid substitutions (G54, P216, F219, M220, G448), resulting in mutated CYP51A enzymes that cannot bind azole drugs. Mechanism B (Overexpression of CYP51A) depicts a green cyp51A gene with a TR34/L98H mutation in the promoter region, leading to increased mRNA transcription and a high concentration of target enzymes. Mechanism C (Overexpression of efflux transporter) illustrates multiple blue cylindrical Cdr1B transporters embedded in the cell membrane, using blue arrows to show the active expulsion of azole drugs (represented by brown triangles) from the intracellular space. This medical illustration provides a clear visual summary of genetic mutations and protein overexpression strategies used by fungal pathogens to evade antifungal treatments targeting the ergosterol synthesis pathway.

Loading Image
Reading File
I now have comprehensive content to write a detailed, well-illustrated answer. Let me compile everything.

Anticholinesterase Drugs

Anticholinesterase drugs (also called cholinesterase inhibitors) act indirectly by inhibiting the enzyme acetylcholinesterase (AChE), which normally cleaves ACh into acetate + choline. By blocking AChE, they allow ACh to accumulate at all cholinergic synapses, amplifying its effects at both muscarinic and nicotinic receptors.

Mechanism of Action

Mechanisms of action of indirect cholinergic agonists - AChE inhibition leads to ACh accumulation and increased intracellular response
AChE is located both pre- and post-synaptically, membrane-bound in the nerve terminal. Its inhibition:
  1. Stimulates muscarinic receptors at ANS effector organs (heart, smooth muscle, glands)
  2. Stimulates then depresses nicotinic receptors at all ANS ganglia and skeletal muscle (NMJ)
  3. Stimulates then depresses CNS cholinergic sites (only with lipid-soluble/tertiary amine drugs)
Most anticholinesterases inhibit both acetylcholinesterase and pseudocholinesterase.
  • Lippincott Illustrated Reviews: Pharmacology, p. 159

Classification

Anticholinesterase Drugs
├── Reversible
│   ├── Short-acting: Edrophonium
│   ├── Intermediate-acting: Physostigmine, Neostigmine, Pyridostigmine, Rivastigmine, Donepezil, Galantamine
│   └── Long-acting (but reversible): Organophosphate-based ophthalmic agents (some)
└── Irreversible
    └── Organophosphates: Echothiophate, Parathion, Malathion, Nerve agents (Sarin, Soman, VX)

I. Reversible Anticholinesterases

A. Short-Acting: Edrophonium

  • Structure: Quaternary amine (cannot cross BBB - peripherally restricted)
  • Mechanism: Binds reversibly to the active center of AChE, electrostatically (no covalent bond)
  • Duration: 10-20 minutes (rapid renal elimination)
  • Uses (historical):
    • Diagnosis of myasthenia gravis (Tensilon test) - IV injection causes rapid, brief improvement in muscle strength in MG patients
    • Assessment of adequacy of treatment with longer-acting cholinesterase inhibitors (distinguishing myasthenic crisis from cholinergic crisis)
    • Note: Edrophonium has been removed from the market due to availability of better diagnostic methods (anti-AChR antibody tests)
  • Katzung's Basic and Clinical Pharmacology, 16th Ed., p. 189; Lippincott, p. 160

B. Intermediate-Acting: Physostigmine

  • Structure: Tertiary amine (natural alkaloid from Calabar bean) - crosses the BBB
  • Mechanism: Carbamic acid ester; forms a stable carbamoylated intermediate with AChE (reversibly inactivated). Duration: 30 min to 2 hours
  • Actions:
    • Stimulates muscarinic + nicotinic sites of ANS
    • Stimulates nicotinic receptors at NMJ (muscle twitches, fasciculations, paralysis at high doses)
    • CNS effects (due to tertiary structure): stimulates central cholinergic sites
  • Therapeutic uses:
    • Reversal of anticholinergic (atropine) overdose - can reverse CNS effects (delirium, coma), unlike neostigmine
    • Historically used in glaucoma
  • Adverse effects: Convulsions at high doses, bradycardia, decreased cardiac output, skeletal muscle paralysis

C. Intermediate-Acting: Neostigmine

  • Structure: Quaternary amine (synthetic carbamic acid ester) - cannot cross BBB
  • Mechanism: Reversible carbamylation of AChE, similar to physostigmine. Duration: 30 min to 2 hours
  • Actions: Greater effect on skeletal muscle than physostigmine; can stimulate then paralyze skeletal muscle
  • Therapeutic uses:
    • Reversal of non-depolarizing neuromuscular blockade (e.g., post-surgery)
    • Myasthenia gravis (symptomatic management)
    • Paralytic ileus and urinary retention (0.5-1 mg SC)
    • Acute colonic pseudo-obstruction (Ogilvie's syndrome)
Before and after neostigmine in Ogilvie's syndrome - abdominal X-ray showing resolution of colonic distension
  • Adverse effects: Salivation, flushing, hypotension, nausea, diarrhea, bronchospasm (generalized cholinergic stimulation). No CNS effects. Contraindicated in mechanical bowel/urinary obstruction
  • Lippincott, p. 161; Katzung, p. 187

D. Pyridostigmine

  • Structure: Quaternary amine - peripherally restricted
  • Longer duration than neostigmine (~3-6 hours)
  • Uses: Chronic management of myasthenia gravis (oral; preferred over neostigmine for long-term use). Also used in nerve agent prophylaxis (military)

E. CNS-Acting Agents (Alzheimer's Disease)

These are long-acting reversible inhibitors used for cognitive enhancement in dementia:
DrugSelectivityDurationNotes
DonepezilAChE > BuChELong (t½ ~70 hrs)First-line; once daily; all stages of AD
RivastigmineAChE + BuChEIntermediateOral/patch; also for Parkinson's dementia
GalantamineAChE + allosteric nicotinic modulatorIntermediateAlso enhances nicotinic receptor sensitivity
TacrineAChE + BuChEShortWithdrawn (hepatotoxicity)

II. Irreversible Anticholinesterases

A. Organophosphates (Echothiophate, Parathion, Malathion, Nerve Agents)

  • Mechanism: Covalently bind via phosphate group to the serine hydroxyl at the active site of AChE → permanent inactivation
  • Recovery requires synthesis of new enzyme molecules
Phosphorylation of acetylcholinesterase by echothiophate, aging process, and reactivation by pralidoxime (2-PAM)
  • Aging: After covalent modification, the phosphorylated enzyme slowly loses one alkyl group ("aging") - making it impossible for pralidoxime to reactivate the enzyme
  • Faster aging agents: Soman (seconds) > Sarin > VX > Echothiophate
  • Echothiophate (historical use): Topical ophthalmic solution for open-angle glaucoma; withdrawn due to risk of cataract formation
  • Parathion/Malathion: Agricultural insecticides; major source of accidental poisoning
  • Nerve agents (Sarin, Soman, VX, Tabun): Chemical warfare agents; act extremely rapidly at high concentrations
  • Lippincott, p. 164-165

III. Pharmacological Effects (SLUDGE + Nicotinic + CNS)

When toxic/overdose levels are reached ("Cholinergic Crisis"):

Muscarinic Effects (SLUDGE / DUMBELS)

SystemEffect
SalivationIncreased
LacrimationIncreased
UrinationIncreased (detrusor contraction)
Defecation / DiarrheaIncreased GI motility
GI crampsNausea, vomiting
EmesisNausea/vomiting
EyeMiosis, blurred vision
HeartBradycardia, heart block
BronchiBronchoconstriction, increased secretions
BPHypotension
Sweat glandsDiaphoresis

Nicotinic Effects (NMJ + Ganglia)

  • NMJ: Muscle fasciculations → weakness → paralysis (depolarizing block)
  • Ganglia: Tachycardia, hypertension (can counteract some muscarinic effects)

CNS Effects (tertiary amines / lipid-soluble organophosphates)

  • Anxiety, restlessness
  • Seizures / convulsions
  • Loss of consciousness, coma
  • Respiratory failure (central + peripheral: bronchospasm + diaphragm paralysis)

IV. Therapeutic Uses Summary

IndicationDrug(s) of Choice
Myasthenia gravis (chronic)Pyridostigmine (oral), neostigmine
Myasthenia gravis (diagnosis)Edrophonium (historical), anti-AChR antibodies now preferred
Reversal of NMB (non-depolarizing)Neostigmine + glycopyrrolate/atropine
Alzheimer's dementiaDonepezil, rivastigmine, galantamine
Anticholinergic overdosePhysostigmine (crosses BBB)
Glaucoma (open-angle)Pilocarpine (direct); echothiophate (historical, withdrawn)
Paralytic ileus / urinary retentionNeostigmine
Ogilvie's syndromeNeostigmine IV

V. Treatment of Anticholinesterase Poisoning (Organophosphate Toxicity)

Clinical Presentation (Cholinergic Crisis)

  • Dominant signs: bronchospasm, excessive secretions, bradycardia, seizures, miosis, diaphoresis, muscle paralysis

Treatment

  1. Pralidoxime (2-PAM) - oxime reactivator of AChE:
    • Must be given before aging occurs (within hours for most agents)
    • Has a charged group that displaces the phosphate from AChE
    • Reverses both peripheral muscarinic and nicotinic effects
    • Does NOT penetrate CNS - cannot reverse central effects
    • Ineffective once aging has occurred, and cannot reverse carbamate (e.g., physostigmine, neostigmine) toxicity
  2. Atropine (high doses) - blocks muscarinic effects (bronchospasm, secretions, bradycardia)
  3. Diazepam - for persistent convulsions
  4. Supportive care: patent airway, oxygen, mechanical ventilation if needed
  • Lippincott Illustrated Reviews: Pharmacology, p. 167; Katzung, p. 193

Key Comparison: Physostigmine vs Neostigmine

FeaturePhysostigmineNeostigmine
StructureTertiary amine (natural)Quaternary amine (synthetic)
BBB penetrationYesNo
GI absorptionGoodPoor
CNS effectsYesNo
Skeletal muscle effectModerateGreater
Main usesAnticholinergic OD reversal, glaucomaNMB reversal, MG, ileus
Atropine reversalYes (peripheral + some CNS)Yes (peripheral only)

Sources: Lippincott Illustrated Reviews: Pharmacology (pp. 159-167) | Katzung's Basic and Clinical Pharmacology, 16th Ed. (pp. 187-193) | Barash's Clinical Anesthesia, 9e | Goodman & Gilman's Pharmacological Basis of Therapeutics

Refer from kd tripathi and other resources which have easy language and understanding which we could write in our exams and can get good marks

Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Searching Images

cholinergic crisis SLUDGE symptoms organophosphate poisoning muscarinic nicotinic

This pathophysiology diagram illustrates the neurotoxic mechanisms of organophosphates (OPs) and their potential link to dissociative disorders. The visual is divided into two primary sections. The left panel depicts the cholinergic damage pathway, showing how OPs inhibit acetylcholinesterase (AChE), the enzyme responsible for breaking down acetylcholine into choline. This inhibition results in high concentrations of acetylcholine, leading to the overstimulation of nicotinic and muscarinic receptors. The downstream consequence is neuronal death within the hypothalamus, thalamus, and basal anterior cerebral cortex. The right panel focuses on non-cholinergic neurotoxicity, where OPs cause direct injury to the serotonergic (red) and dopaminergic (blue) pathways, visualized on a sagittal brain section. Both pathways converge at the bottom of the diagram, suggesting that combined cholinergic, serotonergic, and dopaminergic damage may serve as a pathophysiological substrate for the development of dissociative disorders. The diagram utilizes chemical structures, receptor icons, and anatomical brain maps to synthesize complex biochemical and neurological interactions in the context of pesticide exposure.

This pathophysiology diagram illustrates the neurotoxic mechanisms of organophosphates (OPs) and their potential link to dissociative disorders. The visual is divided into two primary sections. The left panel depicts the cholinergic damage pathway, showing how OPs inhibit acetylcholinesterase (AChE), the enzyme responsible for breaking down acetylcholine into choline. This inhibition results in high concentrations of acetylcholine, leading to the overstimulation of nicotinic and muscarinic receptors. The downstream consequence is neuronal death within the hypothalamus, thalamus, and basal anterior cerebral cortex. The right panel focuses on non-cholinergic neurotoxicity, where OPs cause direct injury to the serotonergic (red) and dopaminergic (blue) pathways, visualized on a sagittal brain section. Both pathways converge at the bottom of the diagram, suggesting that combined cholinergic, serotonergic, and dopaminergic damage may serve as a pathophysiological substrate for the development of dissociative disorders. The diagram utilizes chemical structures, receptor icons, and anatomical brain maps to synthesize complex biochemical and neurological interactions in the context of pesticide exposure.

This medical illustration comprises six sagittal-view diagrams of the human brain (a–f) detailing cholinergic pathways and the distribution of muscarinic receptor subtypes (M1–M5). Diagram (a) maps primary cholinergic inputs, illustrating projections from basal forebrain nuclei, including the medial septum (MS), diagonal band of Broca (DB), and nucleus basalis magnocellularis (nBM), toward the neocortex (frontal, parietal, occipital), amygdala (AMY), and hippocampus (Hc). Brainstem cholinergic projections from the pedunculopontine nucleus (PPN) and laterodorsal tegmentum (LDT) are shown targeting the thalamus and basal forebrain. Panels (b) through (f) utilize color-coded heatmaps to indicate the expression density of muscarinic receptor subtypes: M1 (purple) and M2 (green) show high cortical and hippocampal density; M3 (yellow) is localized primarily in the cortex and basal ganglia; M4 (red) exhibits strong expression in the striatum and neocortex; and M5 (cyan) displays more localized expression in the ventral tegmental area and substantia nigra. These diagrams facilitate understanding of cholinergic neurotransmission relevant to neurodegenerative diseases, epilepsy, and schizophrenia.

This medical illustration comprises six sagittal-view diagrams of the human brain (a–f) detailing cholinergic pathways and the distribution of muscarinic receptor subtypes (M1–M5). Diagram (a) maps primary cholinergic inputs, illustrating projections from basal forebrain nuclei, including the medial septum (MS), diagonal band of Broca (DB), and nucleus basalis magnocellularis (nBM), toward the neocortex (frontal, parietal, occipital), amygdala (AMY), and hippocampus (Hc). Brainstem cholinergic projections from the pedunculopontine nucleus (PPN) and laterodorsal tegmentum (LDT) are shown targeting the thalamus and basal forebrain. Panels (b) through (f) utilize color-coded heatmaps to indicate the expression density of muscarinic receptor subtypes: M1 (purple) and M2 (green) show high cortical and hippocampal density; M3 (yellow) is localized primarily in the cortex and basal ganglia; M4 (red) exhibits strong expression in the striatum and neocortex; and M5 (cyan) displays more localized expression in the ventral tegmental area and substantia nigra. These diagrams facilitate understanding of cholinergic neurotransmission relevant to neurodegenerative diseases, epilepsy, and schizophrenia.

This composite diagnostic image consists of six phosphorimage autoradiograms (A–F) displaying mRNA expression patterns of nicotinic and muscarinic acetylcholine receptor subunits in avian brain sections. Panels A, B, E, and F illustrate nicotinic subunits (CHRNA5, CHRNA7, CHRNA2, and CHRNA2/4 respectively), while panels C and D show muscarinic subunits (CHRM4 and CHRM2). Each panel demonstrates differential signal intensities in grayscale, where darker regions indicate higher gene expression. Black arrows across all panels point to the nucleus HVC (High Vocal Center) in the caudo-dorsal nidopallium, showing notable enrichment for CHRNA5 and CHRM4. Black arrowheads identify the location of Area X in the striatum, which shows particularly intense signal for CHRM4 (panel C) and CHRM2 (panel D). The autoradiograms provide a comparative visualization of neurochemical specializations within the song system, highlighting how specific receptor subunits are localized to different functional nuclei involved in vocal learning and motor control. Scale bar: 1 mm.

This composite diagnostic image consists of six phosphorimage autoradiograms (A–F) displaying mRNA expression patterns of nicotinic and muscarinic acetylcholine receptor subunits in avian brain sections. Panels A, B, E, and F illustrate nicotinic subunits (CHRNA5, CHRNA7, CHRNA2, and CHRNA2/4 respectively), while panels C and D show muscarinic subunits (CHRM4 and CHRM2). Each panel demonstrates differential signal intensities in grayscale, where darker regions indicate higher gene expression. Black arrows across all panels point to the nucleus HVC (High Vocal Center) in the caudo-dorsal nidopallium, showing notable enrichment for CHRNA5 and CHRM4. Black arrowheads identify the location of Area X in the striatum, which shows particularly intense signal for CHRM4 (panel C) and CHRM2 (panel D). The autoradiograms provide a comparative visualization of neurochemical specializations within the song system, highlighting how specific receptor subunits are localized to different functional nuclei involved in vocal learning and motor control. Scale bar: 1 mm.

Loading Image
I have everything needed. Note: KD Tripathi's "Essentials of Medical Pharmacology" is not available in the library, but the content below is written in the same simple, exam-oriented style that KD Tripathi uses - point-by-point, mnemonics, tables, and clear language - drawn from Lippincott, Katzung, and Goodman & Gilman.

ANTICHOLINESTERASE DRUGS

(KD Tripathi-style | Exam-Ready Notes)

Note: KD Tripathi is not in the digital library, but the following is written in the same concise, point-by-point style KD Tripathi is known for, sourced from Lippincott Pharmacology, Katzung, and Goodman & Gilman.

DEFINITION / INTRO (Write this first in exams)

Anticholinesterase drugs (AChE inhibitors / Cholinesterase inhibitors) are drugs that inhibit the enzyme acetylcholinesterase (AChE), which normally breaks down ACh into acetate + choline. By blocking this enzyme, ACh accumulates at the synapse → prolonged and enhanced cholinergic activity at ALL cholinergic synapses.
They are also called indirect-acting cholinomimetics because they do not act directly on receptors - they work by preserving ACh.

CLASSIFICATION (Most important for exams)

ANTICHOLINESTERASE DRUGS
│
├── A. REVERSIBLE
│   ├── 1. Short-acting (minutes)
│   │       Edrophonium (10–20 min)
│   │
│   ├── 2. Intermediate-acting (hours)
│   │       Physostigmine (30 min – 2 hrs) ← tertiary amine
│   │       Neostigmine (30 min – 2 hrs)   ← quaternary amine
│   │       Pyridostigmine (3–6 hrs)        ← quaternary amine
│   │       Ambenonium
│   │
│   └── 3. Long-acting (used in Alzheimer's)
│           Donepezil, Rivastigmine, Galantamine, Tacrine (withdrawn)
│
└── B. IRREVERSIBLE
        Organophosphates:
        Echothiophate (ophthalmic)
        Parathion, Malathion (insecticides)
        Sarin, Soman, VX, Tabun (nerve agents / chemical warfare)
Memory tip: "Every Person Never Avoids Drugs" = Edrophonium, Physostigmine, Neostigmine, Ambenonium (then the rest)

MECHANISM OF ACTION

Anticholinesterase drugs block AChE at the synapse, allowing ACh to accumulate and produce increased intracellular response
Reversible agents:
  • Edrophonium → binds electrostatically (non-covalent) to the anionic site of AChE. Very brief action.
  • Physostigmine, Neostigmine → are carbamic acid esters. They carbamylate the esteratic site of AChE → the enzyme is reversibly inactivated (carbamylated enzyme regenerates slowly over 30 min to 2 hours).
Irreversible agents (Organophosphates):
  • Covalently phosphorylate the serine-OH at the esteratic (active) site of AChE
  • Enzyme is permanently inactivated
  • Recovery only by synthesis of new enzyme (takes weeks)
  • "Aging" = spontaneous loss of one alkyl group from the phosphorylated enzyme → makes the bond absolutely irreversible, even pralidoxime cannot work after aging
(Lippincott Pharmacology, pp. 159-165)

PHARMACOLOGICAL EFFECTS

Since ACh accumulates at ALL cholinergic sites, effects are seen at:

1. Muscarinic effects (SLUDGE mnemonic)

LetterEffect
SSalivation increased
LLacrimation increased
UUrination (detrusor contracts)
DDefecation / Diarrhea
GGI cramps
EEmesis (nausea/vomiting)
Additional muscarinic effects:
  • Eye: Miosis + spasm of accommodation (ciliary muscle contracts)
  • Heart: Bradycardia, reduced cardiac output, hypotension
  • Lung: Bronchoconstriction + increased bronchial secretions
  • Skin: Diaphoresis (sweating)
Physostigmine muscarinic effects - visceral smooth muscle contraction, miosis, hypotension, bradycardia

2. Nicotinic effects (NMJ)

  • Low dose: Muscle fasciculations, increased muscle strength
  • High dose: Depolarizing blockade → muscle weakness → paralysis
  • Also: ganglionic stimulation → tachycardia, hypertension (can mask muscarinic bradycardia)

3. CNS effects (only with tertiary amines - physostigmine, organophosphates)

  • Low dose: Restlessness, anxiety
  • High dose: Tremors, convulsions, coma, respiratory depression
Key exam point: Quaternary amines (neostigmine, pyridostigmine, edrophonium) do NOT cross the BBB → no CNS effects. Tertiary amines (physostigmine) and organophosphates DO cross the BBB → CNS effects occur.

INDIVIDUAL DRUGS (write these one by one in exams)


1. EDROPHONIUM

FeatureDetails
TypeQuaternary amine, short-acting
MechanismElectrostatic binding to anionic site of AChE (no covalent bond)
Duration10-20 minutes (rapidly excreted by kidney)
BBB?NO
UsesDiagnosis of myasthenia gravis (Tensilon test - historically); distinguishing myasthenic crisis from cholinergic crisis
NoteNow removed from market; anti-AChR antibody test is preferred

2. PHYSOSTIGMINE (The most important reversible agent - frequently asked)

FeatureDetails
SourceNatural alkaloid (Calabar bean)
TypeTertiary amine - crosses BBB
MechanismCarbamylates esteratic site of AChE (reversible)
Duration30 min - 2 hrs
BBB?YES (most important feature)
Uses:
  • Antidote for anticholinergic (atropine) poisoning - can reverse BOTH peripheral AND central (delirium, coma) anticholinergic effects. This is its KEY use.
  • Glaucoma (historically, topical)
  • Alzheimer's disease (historical)
Adverse effects:
  • Bradycardia, hypotension
  • Convulsions at high doses
  • Excessive secretions, bronchospasm
  • Skeletal muscle paralysis (at high doses - via NMJ depolarizing block)
Exam tip: "Physostigmine crosses the BBB - so it is used to reverse CNS effects of atropine poisoning. Neostigmine does NOT cross BBB and therefore cannot reverse CNS effects."

3. NEOSTIGMINE (Most clinically used - MUST know)

FeatureDetails
TypeQuaternary amine (synthetic)
MechanismCarbamylates AChE (reversible)
Duration30 min - 2 hrs
BBB?NO
GI absorptionPoor (given parenterally or large oral doses)
Uses:
  1. Reversal of non-depolarizing neuromuscular blockade (post-surgery) - always given WITH atropine/glycopyrrolate to prevent bradycardia
  2. Myasthenia gravis - symptomatic treatment
  3. Paralytic ileus - 0.5-1 mg SC
  4. Urinary retention (post-op, post-partum, non-obstructive)
  5. Ogilvie's syndrome (acute colonic pseudo-obstruction) - IV neostigmine
Adverse effects: Salivation, nausea, diarrhea, abdominal cramps, bronchospasm, bradycardia. No CNS effects.
Contraindicated in: Mechanical intestinal or urinary obstruction (will worsen the problem, may cause perforation or reflux injury to kidneys)

4. PYRIDOSTIGMINE

  • Quaternary amine, similar to neostigmine but longer duration (3-6 hrs)
  • Preferred for chronic oral treatment of myasthenia gravis (neostigmine is used acutely)
  • Also used as prophylaxis against nerve agent (soman) poisoning in military personnel
  • Adverse effects same as neostigmine

5. DONEPEZIL, RIVASTIGMINE, GALANTAMINE (Alzheimer's group)

Why are these used in Alzheimer's? In Alzheimer's disease, there is a deficiency of cholinergic neurons in the cortex → reduced ACh → memory and cognitive decline. AChE inhibitors increase available ACh in the CNS.
DrugSpecial Feature
DonepezilOnce daily (t½ = 70 hrs); mild-moderate-severe AD; well tolerated
RivastigmineInhibits both AChE + BuChE; also for Parkinson's dementia; available as transdermal patch
GalantamineAlso acts as allosteric nicotinic receptor modulator (unique)
TacrineFirst agent; WITHDRAWN due to hepatotoxicity
Common adverse effects: GI disturbances (nausea, vomiting, diarrhea) - most common. Can cause bradycardia.
Exam tip: "None of these drugs stop the progression of Alzheimer's - they only delay it and give modest symptomatic benefit."

6. ORGANOPHOSPHATES (Irreversible agents)

Examples:
  • Echothiophate - ophthalmic use (glaucoma), now mostly withdrawn
  • Parathion, Malathion - agricultural insecticides
  • Sarin, Soman, Tabun, VX - chemical warfare nerve agents
Key feature - "AGING":
Phosphorylation of AChE by echothiophate, aging process, and reactivation by pralidoxime 2-PAM
  1. Organophosphate covalently phosphorylates serine-OH of AChE → enzyme inactive
  2. If left alone → "aging" occurs (loss of one alkyl group)
  3. After aging → enzyme is absolutely irreversible - pralidoxime cannot work
  4. Rate of aging: Soman > Sarin > Tabun > others (soman ages within seconds!)

CHOLINERGIC CRISIS (Organophosphate Poisoning) - Very High Yield

Occurs with organophosphate insecticide poisoning, nerve agent exposure, or AChE inhibitor overdose.
Presentation = SLUDGE (muscarinic) + "KILL" (nicotinic + CNS)
SystemSigns
EyeMiosis (pin-point pupils), blurred vision
GINausea, vomiting, diarrhea, cramps, defecation
GlandsSalivation, lacrimation, sweating (diaphoresis)
RespiratoryBronchoconstriction + excessive secretions → respiratory failure
HeartBradycardia, hypotension
NMJFasciculations → weakness → paralysis of respiratory muscles
CNSAnxiety → seizures → coma (with organophosphates)
Most common cause of death = RESPIRATORY FAILURE (bronchospasm + paralysis of diaphragm + CNS depression)

TREATMENT OF ORGANOPHOSPHATE POISONING (Very Frequently Asked)

Step 1: Supportive care

  • Clear airway, oxygen, mechanical ventilation if needed

Step 2: ATROPINE (given in HIGH doses - life-saving)

  • Blocks muscarinic effects: bronchospasm, secretions, bradycardia
  • Given IV until secretions dry up ("atropinization")
  • Does NOT reverse nicotinic or CNS effects
  • Dose: 2-4 mg IV, repeated every 5-10 min until atropinized

Step 3: PRALIDOXIME (2-PAM) (oxime reactivator)

  • Must be given EARLY before aging
  • Mechanism: Its charged group approaches the anionic site of AChE → displaces the phosphate from AChE → enzyme reactivated
  • Reverses both peripheral muscarinic AND nicotinic effects
  • Does NOT cross BBB → cannot reverse CNS effects
  • Useless after aging of the enzyme
  • Cannot reverse carbamate (physostigmine, neostigmine) toxicity

Step 4: DIAZEPAM

  • Given to control persistent convulsions

COMPARISON TABLE: PHYSOSTIGMINE vs NEOSTIGMINE

(This comparison is a CLASSIC exam question)
FeaturePhysostigmineNeostigmine
SourceNatural (Calabar bean)Synthetic
Chemical typeTertiary amineQuaternary amine
Crosses BBB?YESNO
GI absorptionGoodPoor
CNS effectsYesNo
Effect on skeletal muscleModerateGreater
Used for anticholinergic OD?YES (can reverse CNS effects)NO
Used in myasthenia gravis?Not preferredYES
Used for NMJ reversal?NoYES

USES AT A GLANCE (Quick revision table)

Clinical UseDrug of Choice
Myasthenia gravis (chronic)Pyridostigmine (oral)
Myasthenia gravis (acute/diagnosis)Edrophonium (historical) / Neostigmine
Reversal of non-depolarizing NMBNeostigmine + atropine
Alzheimer's diseaseDonepezil (1st choice), Rivastigmine, Galantamine
Atropine/anticholinergic overdosePhysostigmine (crosses BBB)
Paralytic ileus / urinary retentionNeostigmine
Glaucoma (open angle)Pilocarpine (direct); Echothiophate (historical)
Organophosphate poisoningAtropine + Pralidoxime + Diazepam
Parkinson's dementiaRivastigmine

EXAM-WORTHY ONE-LINERS

  • "Physostigmine is a tertiary amine - the only reversible AChE inhibitor that crosses the BBB."
  • "Neostigmine has greater effect on skeletal muscle than physostigmine."
  • "Pralidoxime works only before aging - give it early in organophosphate poisoning."
  • "Aging is fastest with Soman (seconds) - so 2-PAM is least effective against Soman."
  • "Tacrine = first AChE inhibitor for Alzheimer's - withdrawn due to hepatotoxicity."
  • "Death in organophosphate poisoning = respiratory failure (bronchoconstriction + NMJ paralysis)."
  • "Atropine treats muscarinic effects of AChE poisoning; 2-PAM treats both muscarinic + nicotinic."
  • "Quaternary amines (neostigmine, pyridostigmine, edrophonium) cannot cross BBB."

Sources: Lippincott Illustrated Reviews: Pharmacology (pp. 159-167) | Katzung's Basic and Clinical Pharmacology, 16th Ed. | Goodman & Gilman's Pharmacological Basis of Therapeutics, Chapter 12

Explain me this topic im very new to this i cant understand whats happening

No problem at all! Let me explain this from absolute scratch — like a story. No jargon until you're ready for it.

Anticholinesterase Drugs — Explained Like You're Hearing It for the First Time


STEP 1: First, understand the "messenger" — Acetylcholine (ACh)

Think of your nervous system as a telephone network. Nerves need to send messages to organs (heart, muscles, glands, gut, eyes, etc.).
The messenger chemical that carries these messages is called Acetylcholine (ACh).
When ACh is released from a nerve ending, it travels across a tiny gap (the synapse) and lands on the next cell → that cell receives the message and does its job.
Simple so far? ✓

STEP 2: Now meet the "cleaner" — Acetylcholinesterase (AChE)

Once the message is delivered, the ACh needs to be cleaned up and removed, otherwise the message keeps going forever and the organ goes into overdrive.
The body has a special enzyme called Acetylcholinesterase (AChE) whose ONLY job is to break down ACh after it has done its work.
Think of AChE as a "garbage collector" that cleans up ACh from the synapse.
Nerve → releases ACh → ACh lands on organ → message delivered
                ↓
          AChE comes and DESTROYS ACh
                ↓
         Message stops. System resets.

STEP 3: What happens when you BLOCK the garbage collector?

Now imagine you block AChE — the garbage collector can't clean up. So ACh keeps piling up at the synapse.
More ACh = more and more messages = the organ gets overstimulated.
That is exactly what anticholinesterase drugs do.
They inhibit (block) AChE → ACh accumulates → prolonged, exaggerated cholinergic effect.
ACh accumulates when AChE is blocked, causing increased intracellular response

STEP 4: Where does ACh act? (Two types of receptors)

ACh can act on two types of "receivers" (receptors):
ReceptorWhereEffect when ACh lands
MuscarinicHeart, smooth muscle (gut, lungs, bladder), glands, eyesSlows heart, increases secretions, contracts gut, constricts pupil
NicotinicSkeletal muscle (NMJ), autonomic gangliaContracts muscles
When you give an anticholinesterase drug, ACh builds up → BOTH muscarinic and nicotinic receptors get overstimulated.

STEP 5: What are the EFFECTS of too much ACh?

Muscarinic effects — remember "SLUDGE"

This is what happens when smooth muscles and glands get overstimulated:
SSalivation — mouth fills with saliva
LLacrimation — tears pouring out
UUrination — can't hold urine
DDefecation / Diarrhea — loose stools
GGI cramps — stomach pain
EEmesis — nausea and vomiting
Plus:
  • Eyes: Miosis (pupil becomes very small — "pin-point pupils")
  • Heart: Bradycardia (heart slows down)
  • Lungs: Bronchoconstriction (airways narrow) + lots of mucus secretion → breathing difficulty
  • BP: Falls (hypotension)
  • Skin: Sweating (diaphoresis)
Muscarinic effects - visceral smooth muscle contraction, miosis, hypotension, bradycardia

Nicotinic effects (skeletal muscle):

  • Small dose: Muscle twitching (fasciculations), increased strength
  • Large dose: Muscles get paralyzed (too much stimulation causes the muscle to stop responding — like a phone line overloaded and crashing)

CNS effects (only some drugs):

  • Anxiety → tremors → seizures → coma

STEP 6: The drugs — two big groups

GROUP A: Reversible (temporary blockade of AChE)

These drugs block AChE for a limited time, then AChE comes back to work.
Think of them like "putting a temporary cap on the garbage collector." After some time, the cap falls off and the collector works again.

GROUP B: Irreversible (permanent blockade of AChE)

These drugs permanently destroy AChE. The body has to make brand new AChE enzyme — which takes weeks.
Think of them like "killing the garbage collector permanently."
These are the organophosphate compounds — like insecticides (malathion, parathion) and nerve agents (sarin, soman).

STEP 7: The individual drugs — made simple

1. EDROPHONIUM — "The quick detective"

  • Blocks AChE for only 10-20 minutes, then disappears
  • Was used as a diagnostic test for myasthenia gravis (a disease where muscles are weak — explained below)
  • If a patient has myasthenia gravis and you give edrophonium → muscles become suddenly stronger for a few minutes (because ACh accumulates at the weak NMJ) → confirms diagnosis
  • Cannot enter the brain

2. PHYSOSTIGMINE — "The special one that enters the brain"

  • Blocks AChE for about 30 min to 2 hours
  • The KEY special thing: it is a tertiary aminecan cross the blood-brain barrier (BBB) into the brain
  • Main use: Antidote when someone has atropine/anticholinergic poisoning — because it can reverse both the body AND brain effects of atropine overdose (confusion, delirium, coma)
  • No other common anticholinesterase drug can do this

3. NEOSTIGMINE — "The workhorse"

  • Blocks AChE for 30 min to 2 hours
  • Cannot enter the brain (quaternary amine — too charged/polar)
  • Three big uses:
    1. After surgery, doctors give muscle relaxants to paralyze the patient. When surgery is over, they give neostigmine to reverse this paralysis (always combined with atropine to prevent bradycardia)
    2. Myasthenia gravis — to strengthen weak muscles
    3. Paralytic ileus / urinary retention — to get the gut and bladder moving again

4. PYRIDOSTIGMINE — "The long-lasting neostigmine"

  • Similar to neostigmine, but lasts 3-6 hours (longer)
  • Preferred for daily tablet treatment of myasthenia gravis (because it lasts longer, patient takes fewer tablets)

5. DONEPEZIL / RIVASTIGMINE / GALANTAMINE — "The brain helpers"

  • Used in Alzheimer's disease
  • In Alzheimer's, the brain loses ACh-releasing nerve cells → memory and thinking decline
  • These drugs inhibit AChE in the brain → ACh is preserved → memory and thinking improve (modestly)
  • They do NOT cure Alzheimer's — they slow it down temporarily

STEP 8: What is Myasthenia Gravis? (Because these drugs are very linked to it)

Myasthenia gravis is an autoimmune disease. The body makes antibodies against its own nicotinic receptors at the muscle junction (NMJ). So:
  • Fewer receptors available → ACh cannot deliver its muscle-contracting message properly → muscles become weak
  • Symptoms: drooping eyelids (ptosis), double vision, difficulty swallowing and speaking, limb weakness
  • Treatment: Give neostigmine or pyridostigmine → AChE is blocked → more ACh accumulates → the little ACh that IS available gets to work on the few remaining receptors → muscle strength improves

STEP 9: Organophosphate Poisoning — The scary but important one

Organophosphate insecticides (like malathion used in farms) or nerve agents (like sarin, used in warfare) are irreversible AChE blockers.
When someone is poisoned:
  • AChE is permanently destroyed
  • ACh floods everywhere
  • The person shows ALL of the SLUDGE effects + muscle paralysis + seizures
  • Most common cause of death = Respiratory failure (airways narrow from bronchoconstriction + breathing muscles become paralyzed)

How do you treat it?

3-drug approach:
DrugWhat it does
Atropine (high doses)Blocks muscarinic receptors — stops the SLUDGE effects, opens the airways, raises heart rate. This is the LIFE-SAVING step.
Pralidoxime (2-PAM)"Reactivates" AChE — pulls the organophosphate off the enzyme. Works ONLY if given early, before "aging" happens.
DiazepamStops the seizures

What is "Aging"?

After an organophosphate latches onto AChE, a process called "aging" happens where the bond becomes even stronger and permanent — even pralidoxime cannot break it after this. This is why you must give pralidoxime as early as possible.

THE BIG PICTURE — one diagram in your head

NERVE releases ACh
        ↓
   ACh crosses synapse
        ↓
   ACh binds to receptor → EFFECT (heart slows, muscle contracts, etc.)
        ↓
   AChE breaks down ACh → effect stops
   
   ===================================
   
   GIVE ANTICHOLINESTERASE DRUG:
        ↓
   AChE is BLOCKED → ACh is NOT broken down
        ↓
   ACh piles up → PROLONGED and EXAGGERATED EFFECTS
   (SLUDGE + muscle fasciculations/paralysis + CNS effects)

SUMMARY IN PLAIN ENGLISH

  1. ACh is the nerve messenger. AChE is the enzyme that destroys it.
  2. Anticholinesterase drugs block AChE → ACh piles up → everything gets over-stimulated.
  3. Reversible drugs (neostigmine, physostigmine, pyridostigmine) → useful medicines for myasthenia gravis, reversal of muscle relaxants, Alzheimer's.
  4. Physostigmine is special — only one that enters the brain, used for atropine overdose.
  5. Irreversible drugs (organophosphates) → pesticides/nerve agents → cause SLUDGE + paralysis + seizures + death.
  6. Treatment of poisoning = Atropine (stop SLUDGE) + Pralidoxime (reactivate AChE) + Diazepam (stop fits).

Once you're comfortable with this basic story, the classification, drug names, and mechanisms will all click into place because everything flows logically from "ACh accumulates when AChE is blocked." Start from Step 1 and re-read — let me know which part is still confusing and I'll explain it further!

Try again

Asking for Preferences

Whats the use of these drugs

Here are the uses of anticholinesterase drugs — kept simple and straight to the point.

What Are Anticholinesterase Drugs Used For?

These drugs block the enzyme that destroys ACh (the nerve messenger), so ACh builds up and does MORE work. Doctors use this effect in several situations:

1. 🧠 Myasthenia Gravis (Muscle Weakness Disease)

Drugs: Pyridostigmine, Neostigmine
  • In this disease, muscles become very weak because the body attacks its own nerve-muscle connection
  • These drugs make more ACh available at the muscle → muscle gets stronger
  • Pyridostigmine tablet is taken daily by patients to function normally
  • Think of it as: "boosting the signal to weak muscles"

2. 🏥 Reversing Muscle Paralysis After Surgery

Drug: Neostigmine
  • During surgery, doctors paralyze the patient's muscles (on purpose) using muscle relaxants
  • After surgery is done, they give neostigmine to wake the muscles back up
  • Always given with atropine to prevent the heart from slowing down too much

3. 🧓 Alzheimer's Disease (Memory Loss)

Drugs: Donepezil, Rivastigmine, Galantamine
  • In Alzheimer's, brain cells that make ACh die off → memory and thinking decline
  • These drugs preserve whatever ACh is left in the brain → modest improvement in memory
  • They do NOT cure Alzheimer's — they just slow it down for a while

4. 💊 Antidote for Atropine / Anticholinergic Poisoning

Drug: Physostigmine ONLY
  • If someone takes too much atropine or anticholinergic drug → they get confused, delirious, can go into coma
  • Physostigmine is the only anticholinesterase that enters the brain
  • It reverses both the body AND brain effects of atropine overdose

5. 🚽 Paralytic Ileus and Urinary Retention

Drug: Neostigmine
  • Sometimes after surgery, the gut or bladder "falls asleep" and stops working
  • Neostigmine stimulates the gut and bladder muscles back into action
  • Also used in Ogilvie's syndrome (colon stops working without blockage)

6. 👁️ Glaucoma (High Eye Pressure)

Drug: Echothiophate (historically), now mostly replaced
  • Causes the pupil to constrict (miosis) → helps fluid drain from the eye → lowers eye pressure
  • Largely replaced by better, safer eye drops now

7. 🔍 Diagnosis of Myasthenia Gravis (Historical)

Drug: Edrophonium
  • A very short-acting drug (works for only 10-20 min)
  • If given IV to a myasthenia patient → muscles get suddenly stronger → confirms diagnosis
  • Now replaced by blood tests (anti-AChR antibody test)

Quick Memory Table

UseDrug
Myasthenia gravis (daily treatment)Pyridostigmine
Reversing paralysis after surgeryNeostigmine
Alzheimer's diseaseDonepezil, Rivastigmine, Galantamine
Atropine overdosePhysostigmine
Paralytic ileus / urinary retentionNeostigmine
GlaucomaEchothiophate (historical)
Diagnosing myasthenia gravisEdrophonium (historical)

That's it. Each drug has a specific job. The most important ones to remember for exams are pyridostigmine (myasthenia), neostigmine (surgery reversal + ileus), donepezil (Alzheimer's), and physostigmine (atropine poisoning).
This is a shared conversation. Sign in to Orris to start your own chat.